Contact
searchSearch
HMP Global
Login

Schizophrenia Excellence Forum

Schizophrenia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Brittany Albright
Q&As
Evaluating Anhedonia With Patient-Centered Strategies
03/11/2025
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and A, Brittany Albright, MD, MPH, Psych Congress Elevate faculty member and founder of Sweetgrass Psychiatry, discusses 2 of her favorite anhedonia treatment strategies.
In part 2 of this Q and...
03/11/2025
Psych Congress Network
Dr Brittany Albright
Q&As
Exploring Anhedonia in Psychiatric Care
03/04/2025
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress Elevate faculty member Dr Brittany Albright discusses the challenging symptoms of anhedonia and its significant impact on patients' quality of life and clinical outcomes.
In this Q&A, Psych Congress...
03/04/2025
Psych Congress Network
Examining Novel Treatment Methods in Schizophrenia
Videos
Examining Novel Treatment Methods in Schizophrenia
02/25/2025
Christoph U. Correll, MD
In this discussion, Christoph Correll, MD, professor of psychiatry at the Zucker School of Medicine, delves into the groundbreaking FDA approval of xanomeline/tropsium chloride, a novel treatment for schizophrenia that moves beyond...
In this discussion, Christoph Correll, MD, professor of psychiatry at the Zucker School of Medicine, delves into the groundbreaking FDA approval of xanomeline/tropsium chloride, a novel treatment for schizophrenia that moves beyond...
In this discussion, Christoph...
02/25/2025
Psych Congress Network
Brooke Kempf, PMHNP-BC
Videos
Improving Patient Outcomes With Early Initiation of LAIs
02/05/2025
Brooke Kempf, MSN, PMHNP-BC
What role do long-acting injectables (LAIs) play in improving long-term outcomes for patients with schizophrenia? In this discussion, Brooke Kempf, PMHNP-BC, highlights the benefits of early LAI initiation, from reducing relapse rates and...
What role do long-acting injectables (LAIs) play in improving long-term outcomes for patients with schizophrenia? In this discussion, Brooke Kempf, PMHNP-BC, highlights the benefits of early LAI initiation, from reducing relapse rates and...
What role do long-acting...
02/05/2025
Psych Congress Network
Brooke Kempf
Videos
Addressing Misconceptions About LAI Antipsychotics
01/06/2025
Brooke Kempf, MSN, PMHNP-BC
Kempf emphasizes the power of patient education, addressing myths, and involving families to ease the daily medication burden. 
Kempf emphasizes the power of patient education, addressing myths, and involving families to ease the daily medication burden. 
Kempf emphasizes the power of...
01/06/2025
Psych Congress Network
Andrew Penn, PMHNP-BC
Videos
Best Practices for Deprescribing in Schizophrenia
12/05/2024
Andrew Penn, RN, MS, NP, CNS, APRN-BC
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
In this video, Andrew Penn,...
12/05/2024
Psych Congress Network
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych
Videos
Understanding Antipsychotic-Induced Movement Disorders
12/05/2024
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Rebecca Barbee, MSPAS, PA-C,...
12/05/2024
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Expert Insights Quiz
Prodromal Symptoms of Schizophrenia
11/21/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
11/21/2024
Psych Congress Network
Jonathan Meyer, MD
Videos
Unpacking Negative Symptoms, Medication Adverse Effects, and Emerging Schizophrenia Treatments
11/11/2024
Jonathan Meyer, MD
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his clinical insights on schizophrenia management.
Jonathan Meyer, MD, offers his...
11/11/2024
Psych Congress Network
Christoph Correll, MD.
Videos
Strategies to Manage Adverse Effects From Schizophrenia Treatment
10/28/2024
Christoph U. Correll, MD
Christoph Correll, MD, offers clinical guidance for managing adverse affects from schizophrenia treatment, including weight gain and movement disorder
Christoph Correll, MD, offers clinical guidance for managing adverse affects from schizophrenia treatment, including weight gain and movement disorder
Christoph Correll, MD, offers...
10/28/2024
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use